Reported Friday, Denali Therapeutics Regains Full Rights To DNL593 After Takeda Terminates Collaboration, Phase 1/2 FTD-GRN Trial Results Expected By End Of 2026

Benzinga Newsdesk www.benzinga.com Positive 79.1%

Neg 0% Neu 0% Pos 79.1%

Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to the brain using TransportVehicle™ technology
Results from ongoing Phase 1/2 study in patients with FTD-GRN expected by the end of 2026

Comments

No comments yet. Be the first!